Abstract
Background Monkeypox virus (MPXV) clade Ib, first detected in Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting a WHO emergency declaration. Data on how this clade differs from others, including the incubation period which both shapes outbreak dynamics and informs epidemic response strategies, remain limited.
Methods We use clinical, laboratory and reported exposure data from suspected and qPCR-confirmed mpox cases in Uvira, DRC to estimate the incubation period for MPXV clade 1b. We developed a Bayesian model to estimate incubation periods of various symptom onset definitions (rash, fever, any symptom), demographic factors and putative transmission route (sexual vs. non-sexual).
Results Among 92 PCR-confirmed cases, the median incubation period from exposure to rash was 18.6 days (95% CrI: 15.2-22.6). Five percent of cases are expected to develop a rash within 5.4 days (95% CrI; 3.4-7.6) and 95% within 37.6 days (95% CrI: 30.3-47.0). The incubation period differed by putative transmission route: sexual transmission had a shorter median (9.5 days, 95% CrI 3.7-16.4) than non-sexual transmission (18.9 days, 95% CrI: 15.3-23.0).
Conclusions Incubation periods for clade Ib are longer than previous estimates for other MPXV clades, but vary strongly by sexual vs. non-sexual exposures, the former closely aligning with observations from the predominantly sexually transmitted clade IIa global outbreak. These findings highlight the significant differences by transmission route – likely reflecting differences in infectious viral dose and suggest the need to revise global post-exposure monitoring recommendations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Gates Foundation (INV-079976) and funds from the Geneva Centre for Emerging Viruses. The Gates Foundation had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study were collected with the Uvira health zone team for public health surveillance. Ethical approvals were obtained from the Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health (reference number IRB00030442) and the Universite Catholique de Bukavu (UCB/CIES/NC/019/2024) to use those data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.